70441-03-1

Basic information

• Product Name: 7-HYDROXYSPIRO[CHROMAN-2,1'-CYCLOPENTAN]-4-ONE
• Synonyms: 7-HYDROXYSPIRO[CHROMAN-2,1'-CYCLOPENTAN]-4-ONE;7-hydroxy-3,4-dihydrospiro[1-benzopyran-2,1-cyclopentan]-4-one
• CAS NO: 70441-03-1
• Molecular Formula: C13H14O3
• Molecular Weight: 218.251
• Mol File: 70441-03-1.mol
• Article Data: 11

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 7-HYDROXYSPIRO[CHROMAN-2,1'-CYCLOPENTAN]-4-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 7-HYDROXYSPIRO[CHROMAN-2,1'-CYCLOPENTAN]-4-ONE(70441-03-1)
• EPA Substance Registry System: 7-HYDROXYSPIRO[CHROMAN-2,1'-CYCLOPENTAN]-4-ONE(70441-03-1)

Safety Data

• Hazardous Substances Data: 70441-03-1(Hazardous Substances Data)

Usage

General Description

7-HYDROXYSPIRO[CHROMAN-2,1'-CYCLOPENTAN]-4-ONE is a chemical compound with a spirocyclic ring structure consisting of a chroman ring fused with a cyclopentane ring. It also contains a ketone and a hydroxyl functional group. 7-HYDROXYSPIRO[CHROMAN-2,1'-CYCLOPENTAN]-4-ONE is used in the development of pharmaceuticals and agrochemicals due to its potential biological activities, including antioxidant and anti-inflammatory properties. Its unique structure and reactivity make it a valuable intermediate in organic synthesis, particularly in the preparation of complex natural products and drug molecules. Additionally, 7-HYDROXYSPIRO[CHROMAN-2,1'-CYCLOPENTAN]-4-ONE has potential applications in materials science and the development of functional organic materials.

Upstream product

• 1903-27-1 cyclopentylidene acetic acid 
• 108-46-3 recorcinol 
• 93467-44-8 7-methoxy-2-spiropentyl-2,3-dihydrochromen-4-one 
• 89-84-9 2',4'-dihydroxy-4-acetophenone 
• 120-92-3 cyclopentanone 
• 65490-08-6 2-hydroxy-4-(methoxymethoxy)acetophenone 

Downstream Products

• 1426137-29-2 C₂₅H₃₁NO₄ 
• 1426137-30-5 C₂₃H₂₇NO₅ 
• 1426137-31-6 C₂₂H₂₄FNO₄ 
• 1426137-32-7 C₂₃H₂₇NO₅ 
• 1426137-33-8 C₂₅H₃₁NO₄ 
• 1426137-34-9 C₂₂H₂₄N₂O₇ 
• 1426137-35-0 C₂₄H₂₉NO₅ 
• 1426137-26-9 C₂₂H₂₅NO₄ 
• 1426137-27-0 C₂₃H₂₇NO₄ 
• 1426137-28-1 C₂₂H₂₄ClNO₄ 

Relevant articles and documents

Design, Synthesis and Biological Investigation of Flavone Derivatives as Potential Multi-Receptor Atypical Antipsychotics

The design of a series of novel flavone derivatives was synthesized as potential broad-spectrum antipsychotics by using multi-receptor affinity strategy between dopamine receptors and serotonin receptors. Among them, 7-(4-(4-(6-fluorobenzo[d]isoxazol-3-yl) piperidin- 1-yl) butoxy)-2,2-dimethylchroman-4-one (6j) exhibited a promising preclinical profile. Compound 6j not only showed high affinity for dopamine D2, D3, and serotonin 5-HT1A, 5-HT2A receptors, but was also endowed with low to moderate activities on 5-HT2C, α1, and H1 receptors, indicating a low liability to induce side effects such as weight gain, orthostatic hypotension and QT prolongation. In vivo behavioral studies suggested that 6j has favorable effects in alleviating the schizophrenia-like symptoms without causing catalepsy. Taken together, compound 6j has the potential to be further developed as a novel atypical antipsychotic.

Synthesis and antitubercular activity of amino alcohol fused spirochromone conjugates

A series of 21 new amino alcohol fused spirochromone conjugates have been synthesized, characterized with analytical data and evaluated their antimycobacterial activity against Mycobacterium tuberculosis (virulent strain H37Rv) in vitro. Some of the compounds exerted significant inhibition, in particular, compound 4f found to be the most potent derivative exhibiting MIC = 3.13 μg/mL.

Development of a benzopyran-containing androgen receptor antagonist to treat antiandrogen-resistant prostate cancer

Antagonizing cancer 2 000 druglike small molecules were screened and a scaffold identified as a potentially novel androgen receptor antagonist framework. A focused library of 19 derivatives was then synthesized and evaluated in vitro against LNCaP prostate cancer cell line. A novel compound (6 f) was identified as a promising lead compound for the further development of new therapeutic agents against hormone-refractory prostate cancer.